Leukemia Cell Cultures for Research of New Anti-Cancer Therapies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by University Hospital, Strasbourg, France.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00993538
First received: October 9, 2009
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims:

  • To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.
  • To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.
  • To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.

Condition Intervention
Acute Leukaemia
Procedure: Blood sampling
Procedure: Bone marrow aspiration

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Leukemia Cell Cultures for Research of New Anti-cancer Therapies

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment: 180
Study Start Date: July 2009
Arms Assigned Interventions
Experimental: 1 Procedure: Blood sampling Procedure: Bone marrow aspiration

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis
  • Patients older or equal than 28 days
  • Informed consent signed

Exclusion Criteria:

  • Pregnancy
  • Breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00993538

Contacts
Contact: Raoul Herbrecht, MD 3.33.88.12.83.79 Raoul.herbrecht@chru-strasbourg.fr
Contact: Patrick lutz, MD 3.33.88.12.80.90 Patrick.lutz@chru-strasbourg.fr

Locations
France
Service d'Hématologie et d'Oncologie Recruiting
Strasbourg, France, 67098
Contact: Raoul Herbrecht, MD    3.33.88.12.83.79    Raoul.herbrecht@chru-strasbourg.fr   
Principal Investigator: Raoul Herbrecht, MD         
Sub-Investigator: Cécile Fohrer, MD         
Sub-Investigator: Luc Fornecker, MD         
Sub-Investigator: Bruno Lioure, MD         
Sub-Investigator: Karin Bilger, MD         
Service de Pédiaterie - Hôpital de Hautepierre Recruiting
Strasbourg, France, 67098
Contact: Patrick Lutz, MD    3.33.88.12.80.90    Patrick.lutz@chru-strasbourg.fr   
Principal Investigator: Patrick Lutz, MD         
Sub-Investigator: Natacha Entz-Werle, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Raoul Herbrecht, MD Département d'Hématologie et d'Oncologie-hôpital de Hautepierre Strasbourg, France
  More Information

No publications provided

Responsible Party: Christine GEILLER/Directeur de la Recherche Clinique et des Innovations, University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00993538     History of Changes
Other Study ID Numbers: 4452
Study First Received: October 9, 2009
Last Updated: August 29, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Strasbourg, France:
Leukaemia
Blood and marrow cells culture
Cell growth
Cell differentiation

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on September 30, 2014